Nature Reviews Gastroenterology & Hepatology

Papers
(The TQCC of Nature Reviews Gastroenterology & Hepatology is 16. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Regulating protease homeostasis in irritable bowel syndrome730
Hybrid EASL Congress 2023528
Immunosuppressive IBD drugs and COVID-19 vaccine immunogenicity497
Zolbetuximab treatment in metastatic gastric cancer495
Unlocking CD8+ T cell potential in chronic hepatitis B virus infection484
Mirikizumab for inducing and maintaining clinical remission in ulcerative colitis425
Celebrating 20 years of Nature Reviews Gastroenterology & Hepatology412
Digestive Disease Week 2022374
Mapping neuroimmune interactions in the gut362
Author Correction: Towards unifying fatty liver nomenclature: a voice from the Middle East and North Africa332
2023 FDA approvals in gastroenterology and hepatology326
New potent HBV replication inhibitors for the management of chronic hepatitis B are needed323
Western lifestyle, metaflammation and the cell of origin of colon cancer319
The role of the enteric nervous system in the pathogenesis of Clostridioides difficile infection311
Large language models for clinical decision support in gastroenterology and hepatology299
Black–White disparities across the colorectal cancer care continuum in the USA280
Helicobacter pylori, microbiota and gastric cancer — principles of microorganism-driven carcinogenesis245
Leveraging diet to engineer the gut microbiome226
Nomenclature of HBV core protein-targeting antivirals224
Artificial intelligence and automation in endoscopy and surgery215
Hepatic IRF3 in glucose intolerance209
Oral microbiome therapy efficacious for recurrent C. difficile infection195
Wound healing in the colon190
GWAS reveals variants for alcohol-related hepatocellular carcinoma187
A crucial Fusobacterium nucleatum clade in colorectal cancer185
The global burden of coeliac disease: opportunities and challenges183
CAR T cell therapies in gastrointestinal cancers: current clinical trials and strategies to overcome challenges180
Inflammatory bowel disease in pregnancy and breastfeeding175
Decoding therapy resistance in liver tumours: a giant leap171
New understanding of hepatobiliary MRI169
Lessons from incretin-based therapy in MASH and obesity165
Metastatic pancreatic cancer and the liver162
The gut–brain axis and pain signalling mechanisms in the gastrointestinal tract160
Bacteriophages and their potential for treatment of gastrointestinal diseases159
The changing metabolic landscape of bile acids – keys to metabolism and immune regulation154
Integrated systems approach to identify environmental factors in intestinal inflammation149
Hepatocyte-derived biomarkers in alcohol-related cirrhosis143
A greener gastroenterology: challenges and opportunities for an eco-sustainable approach to digestive diseases132
Metabolic diseases in the East Asian populations131
Lanifibranor and NASH resolution130
Implications of the evolving knowledge of the genetic architecture of MASLD128
Estimating dietary intake from human stool DNA123
Characterizing the genomic landscape of colorectal cancer118
HDCA ameliorates NAFLD in mice116
Probiotics for preterms: sharing complex decision-making115
The path to successful hepatitis C elimination in Spain113
Liver, ageing and disease113
SSRIs and depression: role of gut–brain communication112
A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook110
Irritable bowel syndrome and mental health comorbidity — approach to multidisciplinary management109
Medical therapy of paediatric inflammatory bowel disease106
Human intestinal B cells in inflammatory diseases106
Author Correction: Μetabolic dysfunction-associated steatotic liver disease: a condition of heterogeneous metabolic risk factors, mechanisms and comorbidities requiring holistic treatment102
Current and future colorectal cancer screening strategies101
Preventing the progression of cirrhosis to decompensation and death100
ECCO’2499
Author Correction: Hepatic immune regulation and sex disparities99
NAFLD prevalence in older patients with T2DM96
Phase III results for first-line treatment for metastatic colorectal cancer95
Microbiota and colorectal cancer — controlling for confounders challenges associations94
Gut microbiome and autism spectrum disorder93
Enteric nervous system transfers stress to the gut91
GLP1R agonists in NAFLD: a promising therapy on the horizon88
Reply to ‘Incorporating genetic variations in alcohol-associated liver disease trials for East Asian populations’87
Transforming the landscape of liver cancer detection and care86
Artificial intelligence in liver cancer — new tools for research and patient management85
Risk minimization of JAK inhibitors in ulcerative colitis following regulatory guidance85
Neutrophils as potential therapeutic targets in hepatocellular carcinoma81
The future of pathology in gastroenterology and hepatology80
Foundations of gastrointestinal-based drug delivery and future developments79
Hepatic glucose metabolism in the steatotic liver77
Hepatic inflammatory responses in liver fibrosis76
Immunoregulatory role of enteric glia74
Liver dialysis in ACLF74
SMART cancer risk prediction74
AI predicts pancreatic cancer risk71
Elucidating the transmission landscape of the human microbiome69
Gut bacteria go on record65
Author Correction: Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel64
Postbiotics — when simplification fails to clarify60
A global consensus on the definitions, diagnosis and management of fibrostenosing small bowel Crohn’s disease in clinical practice59
International collaborative research to improve gallbladder cancer prevention59
MASLD as a non-communicable disease56
Nifty new tools for microbiome treatment design56
Future direction of total neoadjuvant therapy for locally advanced rectal cancer54
Hepatitis E virus: from innate sensing to adaptive immune responses54
A new era in obesity management52
Nutrient sensing and small intestinal enteric neurons51
Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests50
Revisiting fibrosis in inflammatory bowel disease: the gut thickens50
Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms49
Danger! P2Y14 receptor links cell death to liver fibrosis48
Tirzepatide to treat obesity: phase III results47
A novel pathomics signature for gastric cancer47
Cathepsin S in liver fibrogenesis47
Bridging the gap: increasing MENA representation in MASLD clinical trials42
Natural history of NAFLD: knowns and unknowns42
Antibiotic-perturbed microbiota and the role of probiotics40
Therapeutic landscape and future direction of metastatic colorectal cancer38
The steatotic liver disease burden paradox: unravelling the key role of alcohol38
Origin of CAFs in colorectal cancer37
Classifying compounds as prebiotics — scientific perspectives and recommendations36
Cellular and molecular basis of proximal small intestine disorders35
Changing epidemiology of colorectal cancer — birth cohort effects and emerging risk factors34
Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer34
Telemedicine for hepatitis C virus treatment in opioid treatment programmes31
Commensal fungi in intestinal health and disease31
Long-term normothermic liver perfusion30
Equitable partnerships and the path to inclusive, innovative and impactful human microbiome research30
Author Correction: Improving IBD outcomes in the era of many treatment options30
Alcohol-free and low-strength drinks: friend or foe?29
Justice, equity, diversity and inclusion in gastroenterology and hepatology29
Public health policies to prevent alcohol-related liver disease29
Author Correction: Current and future colorectal cancer screening strategies28
Antifibrotic therapy in nonalcoholic steatohepatitis: time for a human-centric approach28
Pleasurable and problematic receptive anal intercourse and diseases of the colon, rectum and anus27
Diet-driven microbiome restoration associated with cardiometabolic benefits27
Sphingosine 1-phosphate modulation and immune cell trafficking in inflammatory bowel disease26
A Roadmap for the Human Gut Cell Atlas26
Global epidemiology of cirrhosis — aetiology, trends and predictions25
Resmetirom safe for nonalcoholic fatty liver disease25
Hippo signalling in the liver: role in development, regeneration and disease25
New target and timing in PDAC immunotherapy?25
Digestive Disease Week 202324
A resource for the food microbiome and its links with the human microbiome23
ECCO’2523
Elafibranor in primary biliary cholangitis23
Food inequity and insecurity and MASLD: burden, challenges, and interventions22
Envisioning how to advance the MASH field22
Intermittent fasting for NASH and HCC in mice21
Location, location, location — spatial insight into hepatic macrophage populations21
Deciphering potential implications of dietary microplastics for human health21
Digestive Disease Week 202521
Nanoparticles in NAFLD therapeutics20
Gastrointestinal health and the environment: a bidirectional relationship20
Follow-up of SER-109 for recurrent C. difficile20
Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions20
Human liver tissue in a mouse host20
HCV direct-acting antiviral therapy adherence in people who inject drugs19
RNA vaccine induces long-lived anti-tumour T cells in pancreatic cancer19
Autocrine signalling discovery reveals potential therapeutic targets in NASH fibrosis19
Amitriptyline as second-line treatment for IBS in primary care settings19
Lactylation and HCC progression18
IL-17A-producing CD8+ T cells in pancreatic cancer18
COVID-19 and liver disease: where are we now?18
Gastrointestinal post-acute COVID-19 syndrome17
Hepatocellular carcinoma surveillance — utilization, barriers and the impact of changing aetiology17
The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease16
Paving the way: the road to be taken for proper NAFLD health care16
Circadian regulation of liver function: from molecular mechanisms to disease pathophysiology16
Biologic agents for IBD come of age as host–microbe interactions emerge16
0.12365889549255